AASLD 2011:Similar Virologic Response to Entecavir 0.5 mg or 1.0 mg Daily in Tre

StephenW

Similar Virologic Response to Entecavir 0.5 mg or 1.0 mg Daily in Treatment-Naive Chronic Hepatitis B Patients: A Case-Control Study
Mr. Nghiem Ha                                                                        
                                                        
United States of America                          
                                                                                                                                Purpose: The dosage recommendation for ETV is 0.5 mg daily for treatment-naïve chronic hepatitis B (CHB) patients and 1.0 mg daily for lamivudine-refractory patients; however, little data is available for the efficacy of 1.0 mg daily dosage in treatment-naïve CHB patients. Our goal is to examine treatment outcome of
treatment-naïve patients treated with either ETV 0.5 mg or ETV 1.0 mg daily.

Methods: Cases included 40 consecutive CHB patients treated with ETV 1.0 mg daily between 1/2005-9/2010 at 3 U.S. clinics, and controls were 40 consecutive CHB patients treated with ETV 0.5 mg daily between 1/2005-9/2010 at the
same clinics and matched for age (±5 years), gender, hepatitis B e antigen (HBeAg) status, baseline ALT (±10 U/L), and baseline HBV DNA (±0.5 log10 IU/mL). Complete viral suppression was defined as undetectable HBV DNA (<100
IU/mL).

Results: Baseline characteristics were similar in cases and controls: median age=35–36 years, proportion of male patients=55%, proportion of HBeAg positive=100%, median serum ALT=40–60 U/L, and median serum HBV DNA=8.08–8.19 log10 IU/mL. The rate of complete viral suppression was similar in both cohorts through week 24 and week 48 (Figure 1). By week 48, 3 patients in the ETV 0.5 mg daily controls achieved HBeAg seroconversion.

Conclusions: Complete viral suppression rate was similar in patients treated with ETV 0.5 mg daily or the higher daily dose of 1.0 mg at 24 weeks and 48 weeks.

StephenW

目的：ETV剂量建议是治疗过的慢性乙型肝炎（CHB）患者和1.0毫克拉米夫定难治性患者每天的每天0.5毫克;，然而，很少的数据是1.0毫克剂量的疗效，在治疗过慢性乙型肝炎患者。我们的目标是研究治疗成果
治疗过治疗的患者，ETV0.5毫克或1.0毫克，每日ETV。

方法：个案中包括40个连续慢性乙型肝炎1/2005-9/2010与ETV1.0毫克，每日3美国诊所治疗的患者，和对照组连续40之间1/2005-9/2010ETV0.5毫克，每日在慢性乙型肝炎治疗的患者
同样的诊所和年龄（±5岁），性别，乙肝e抗原（HBeAg）状态，基线ALT（±10）U / L，与基线HBV DNA（±0.5 log10的国际单位/毫升）相匹配。被定义为完全抑制病毒检测不到乙肝病毒DNA（<100
国际单位/毫升）。

结果：在病例组和对照组基线特征相似：年龄中位数=35-36岁，男性患者的比例= 55％，HBeAg的积极=100％，血清ALT中位数=40〜60 U / L和中位数血清HBV比例DNA=8.08-8.19 LOG10国际单位/毫升。完整的病毒抑制率是相似的（图1）通过24周和48周的两个同伙。第48周，在ETV
0.5毫克，每日3例患者控制实现HBeAg血清转换。

结论：完整的病毒抑制率与ETV0.5毫克或1.0毫克，每日剂量在24周和48周治疗的患者相似。

tonychant

W斯蒂芬总是给我们带来不错的信息，谢谢！